Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
Total Valuation
Passage Bio has a market cap or net worth of $23.68M. The enterprise value is -$7.52M.
Market Cap$23.68M
Enterprise Value-$7.52M
Share Statistics
Passage Bio has 3,120,295 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,120,295
Owned by Insiders26.55%
Owned by Institutions<0.01%
Financial Efficiency
Passage Bio’s return on equity (ROE) is -1.06 and return on invested capital (ROIC) is -81.16%.
Return on Equity (ROE)-1.06
Return on Assets (ROA)-0.63
Return on Invested Capital (ROIC)-81.16%
Return on Capital Employed (ROCE)-0.85
Revenue Per Employee0.00
Profits Per Employee-1.08M
Employee Count60
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Passage Bio is ―. Passage Bio’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.56
Price to FCF―
Price to Operating Cash Flow-0.56
PEG Ratio―
Income Statement
In the last 12 months, Passage Bio had revenue of 0.00 and earned -64.77M in profits. Earnings per share was -21.44.
Revenue0.00
Gross Profit-3.08M
Operating Income-70.40M
Pretax Income-64.77M
Net Income-64.77M
EBITDA-61.69M
Earnings Per Share (EPS)-21.44
Cash Flow
In the last 12 months, operating cash flow was -36.07M and capital expenditures -34.00K, giving a free cash flow of -36.10M billion.
Operating Cash Flow-36.07M
Free Cash Flow-36.10M
Free Cash Flow per Share-11.57
Dividends & Yields
Passage Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change-52.40%
50-Day Moving Average7.08
200-Day Moving Average9.62
Relative Strength Index (RSI)53.66
Average Volume (3m)80.53K
Important Dates
Passage Bio upcoming earnings date is Nov 18, 2025, Before Open (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Passage Bio as a current ratio of 4.07, with Debt / Equity ratio of 64.64%
Current Ratio4.07
Quick Ratio4.07
Debt to Market Cap0.11
Net Debt to EBITDA0.20
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Passage Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Passage Bio EV to EBITDA ratio is -0.36, with an EV/FCF ratio of -0.46.
EV to Sales0.00
EV to EBITDA-0.36
EV to Free Cash Flow-0.46
EV to Operating Cash Flow-0.46
Balance Sheet
Passage Bio has $57.63M in cash and marketable securities with $24.73M in debt, giving a net cash position of -$32.90M billion.
Cash & Marketable Securities$57.63M
Total Debt$24.73M
Net Cash-$32.90M
Net Cash Per Share-$10.54
Tangible Book Value Per Share$20.28
Margins
Gross margin is 12.61%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin12.61%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Passage Bio is $59.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$59.25
Price Target Upside752.52% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast32.57%